MrMed Plans Expansion Into Allied Super-Specialty Healthcare Services

The move is intended to improve last-mile access and reduce fulfilment timelines, particularly for life-saving and temperature-sensitive medicines.

Chennai-based startup MrMed, a direct-to-patient platform focused on critical care and super-specialty medicines, has announced a new phase of expansion aimed at strengthening its physical infrastructure, enhancing cold-chain capabilities, and broadening its healthcare offerings across India.

As part of its growth strategy, MrMed has expanded its on-ground operations to Guwahati, adding to its existing presence in Chennai, Delhi, and Bengaluru. The move is intended to improve last-mile access and reduce fulfilment timelines, particularly for life-saving and temperature-sensitive medicines.

Recognising the operational challenges associated with delivering critical therapies, the company has also launched an offline cold-chain storage facility in Bengaluru. The facility is expected to support faster fulfilment and improved patient access across Karnataka and the wider South India region. Chennai will continue to function as MrMed’s central operations and pharmacy hub.

In addition to the recent developments, MrMed stated that it is advancing plans to expand its physical infrastructure to more cities across the country. The focus remains on strengthening last-mile delivery capabilities for critical and cold-chain-dependent medicines, which often require strict handling and storage protocols.

Beyond logistics and distribution, MrMed is expanding its role within the healthcare ecosystem by entering allied super-specialty healthcare services. The company plans to introduce home-based cancer care offerings, including nurse-led infusions and pre- and post-chemotherapy support. These services are aimed at reducing the need for repeated hospital visits and supporting continuity of care for patients undergoing long-term treatment cycles.

The expansion into allied services marks a shift beyond medicine delivery, positioning the company closer to direct patient care in select therapeutic areas. The planned offerings are expected to complement MrMed’s existing focus on critical and super-specialty medicines.

MrMed currently works with authorised distributors of Indian and global pharmaceutical companies, including Eli Lilly, Novo Nordisk, Cipla, Dr Reddy’s, and Mankind. The company sources medicines through compliant channels to ensure access to approved therapies for patients across multiple regions.

Stay tuned for more such updates on Digital Health News